Latest news with #Alpha-CORRECT
Yahoo
29-04-2025
- Business
- Yahoo
US High Growth Tech Stocks to Watch
The United States market has experienced a notable upswing, rising 7.1% over the last week and climbing 7.7% in the past year, with earnings forecasted to grow by 14% annually. In this context of growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to evolving market trends. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 20.27% 29.79% ★★★★★★ Alkami Technology 20.46% 85.16% ★★★★★★ Travere Therapeutics 28.65% 66.06% ★★★★★★ TG Therapeutics 26.06% 37.39% ★★★★★★ Arcutis Biotherapeutics 26.11% 58.46% ★★★★★★ Clene 62.08% 64.01% ★★★★★★ Alnylam Pharmaceuticals 23.08% 58.85% ★★★★★★ AVITA Medical 27.81% 55.17% ★★★★★★ Lumentum Holdings 21.34% 120.49% ★★★★★★ Ascendis Pharma 32.75% 59.64% ★★★★★★ Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Exact Sciences Corporation develops and markets cancer screening and diagnostic test products globally, with a market cap of approximately $8.44 billion. Operations: The company generates revenue primarily from its biotechnology segment, totaling approximately $2.76 billion. Its focus on cancer screening and diagnostic tests positions it within the healthcare sector, targeting both domestic and international markets. Exact Sciences is making significant strides in the high-growth tech sector, particularly with its recent advancements in cancer diagnostics. The launch of Oncodetect, a test for detecting molecular residual disease across multiple solid tumors, showcases their commitment to innovation; this test enhances treatment decisions and monitoring with its ability to detect one ctDNA molecule among 20,000 cfDNA molecules. With an R&D expense ratio that has consistently been above industry average at 15% of revenue, Exact Sciences is not just expanding its product line but also ensuring these innovations reach a broad audience through strategic Medicare collaborations and robust clinical validations like the Alpha-CORRECT study. This approach not only secures their position in precision medicine but also aligns with broader healthcare trends towards personalized care solutions. Get an in-depth perspective on Exact Sciences' performance by reading our health report here. Review our historical performance report to gain insights into Exact Sciences''s past performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: DigitalOcean Holdings, Inc. operates a cloud computing platform serving customers in North America, Europe, Asia, and other international markets with a market cap of $2.83 billion. Operations: DigitalOcean generates revenue primarily from its Internet Software & Services segment, which reported $780.62 million. The company focuses on providing cloud computing solutions across various global markets. DigitalOcean Holdings, Inc. (DOCN) has demonstrated robust growth and innovation in the tech sector, particularly with its recent product enhancements and strategic acquisitions. The company reported a significant 335.3% earnings growth over the past year, driven by smart expansions like the acquisition of Cloudways and Paperspace, which bolstered both revenue streams and technological capabilities. Its R&D spending is strategically aligned with its growth trajectory, ensuring continual innovation in cloud infrastructure services. With an anticipated annual revenue increase of 12.3% and earnings expected to rise by 23% per year, DOCN is effectively leveraging technological advancements to enhance scalability and performance for its clients. Recent launches like DigitalOcean Managed Caching for Valkey highlight its commitment to high-performance solutions that cater to dynamic market needs while maintaining competitive pricing structures. Unlock comprehensive insights into our analysis of DigitalOcean Holdings stock in this health report. Gain insights into DigitalOcean Holdings' historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Grindr Inc. operates a social networking and dating application catering to the LGBTQ communities globally, with a market cap of approximately $4.39 billion. Operations: The company generates revenue primarily through its role as an Internet Information Provider, with reported figures of $344.64 million. Grindr's strategic expansions and innovative features, such as the recent rollout of "Right Now" in major cities worldwide, underscore its commitment to enhancing real-time user engagement. Despite being unprofitable with a significant net loss of $131 million in 2024, the company has managed to increase its revenue by 17.4% annually, outpacing the US market average of 8.2%. This growth is supported by a robust R&D focus which aligns with projected profitability within three years and an expected annual earnings increase of 46.18%. Moreover, Grindr's proactive approach in repurchasing $500 million worth of its stock signals confidence in its financial strategy and future market position. Dive into the specifics of Grindr here with our thorough health report. Evaluate Grindr's historical performance by accessing our past performance report. Dive into all 233 of the US High Growth Tech and AI Stocks we have identified here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:EXAS NYSE:DOCN and NYSE:GRND. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Business Wire
22-04-2025
- Health
- Business Wire
Exact Sciences Launches the Oncodetect ™ Molecular Residual Disease Test
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing. The Oncodetect test delivers clear "Detected' or 'Not Detected' results, accompanied by quantitative data to help support adjuvant therapy decisions, evaluate treatment response, and monitor cancer recurrence. Notably, patients who test positive for ctDNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results 1. Highly sensitive and personalized, the test tracks up to 200 tumor-specific variants and identifies even trace amounts of ctDNA—down to 1 ctDNA molecule in 20,000 cfDNA ‡ molecules. This sensitivity enables earlier detection of CRC recurrence compared to imaging alone 1,2. "Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions," said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences. "After surgery and definitive therapy, such as chemotherapy or radiation, the risk for cancer recurrence remains a major concern. Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.' Backed by robust clinical validation, including data from the Alpha-CORRECT study—one of the longest-followed MRD cohorts for CRC recurrence with nearly five years of follow-up—the Oncodetect test enhances understanding of cancer recurrence and helps support timely, personalized treatment decisions. Exact Sciences is actively working with Medicare to secure reimbursement for the test, ensuring broad patient access nationwide. The company is also advancing clinical and analytical validation studies across multiple solid tumors, supported by strategic partnerships for multi-cancer evidence generation. 'Exact Sciences is a longtime trusted partner in addressing the critical unmet needs in colorectal cancer care, ensuring patients have the insights they need to navigate treatment with confidence,' said Vanessa Ghigliotty, Certified Patient Navigator & Chair, Patient Advisory Board, GI Cancers Alliance §. 'For those facing the uncertainty of recurrence, tumor-informed MRD tests like the Oncodetect test can provide clear, timely answers—empowering patients to take an active role in their care and receive the right treatment at the right time for better outcomes.' The Oncodetect test builds on 20 years of genomic testing excellence established by the Oncotype DX Breast Recurrence Score ® test. Integrated into a world-class digital experience, supported by the ExactNexus™ technology platform, the Oncodetect test can be ordered with other Exact Sciences tests, including OncoExTra ® (comprehensive genomic profiling) and Riskguard® (hereditary cancer testing). With more than 3 million American patients 3 eligible for MRD testing, Exact Sciences is well-positioned to shape the future of personalized care. The Oncodetect test is now available. For more information, visit * Circulating tumor DNA † The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test's clinical validation. ‡ Cell-free DNA § Ghigliotty attended the March 2025 Cologuard Classic through a grant from Exact Sciences to the GI Cancers Alliance, which has also received prior funding from the company. References Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology. Santonja et al 2023 EMBO ( Data source on file Internal product profile of the Oncodetect test About the Oncodetect test Developed by Exact Sciences, the Oncodetect test is a tumor-informed molecular residual disease (MRD) test designed to provide a personalized approach to detecting and monitoring residual cancer in patients with solid tumors. By leveraging the company's expertise in whole exome sequencing, the Oncodetect test analyzes circulating tumor DNA (ctDNA) shed into the bloodstream by tumors, offering critical insights into changes in ctDNA levels over time. This quantitative assessment of ctDNA (measured as MTM/mL) helps healthcare providers better understand a patient's MRD status and make informed treatment decisions 4. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook. Oncodetect, Oncotype, Oncotype DX Breast Recurrence Score, and OncoExTra are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences, Cologuard, and Riskguard are trademarks of Exact Sciences Corporation. Oncodetect, Cologuard, Riskguard, and OncoExTra are only available in the United States. Forward-Looking Statement This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding our expectations for the commercialization of the Oncodetect test and the performance of the Oncodetect test in a commercial setting. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Business Wire
22-04-2025
- Health
- Business Wire
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing. The Oncodetect test delivers clear "Detected' or 'Not Detected' results, accompanied by quantitative data to help support adjuvant therapy decisions, evaluate treatment response, and monitor cancer recurrence. Notably, patients who test positive for ctDNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results1. Highly sensitive and personalized, the test tracks up to 200 tumor-specific variants and identifies even trace amounts of ctDNA—down to 1 ctDNA molecule in 20,000 cfDNA‡ molecules. This sensitivity enables earlier detection of CRC recurrence compared to imaging alone1,2. "Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions," said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences. "After surgery and definitive therapy, such as chemotherapy or radiation, the risk for cancer recurrence remains a major concern. Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.' Backed by robust clinical validation, including data from the Alpha-CORRECT study—one of the longest-followed MRD cohorts for CRC recurrence with nearly five years of follow-up—the Oncodetect test enhances understanding of cancer recurrence and helps support timely, personalized treatment decisions. Exact Sciences is actively working with Medicare to secure reimbursement for the test, ensuring broad patient access nationwide. The company is also advancing clinical and analytical validation studies across multiple solid tumors, supported by strategic partnerships for multi-cancer evidence generation. 'Exact Sciences is a longtime trusted partner in addressing the critical unmet needs in colorectal cancer care, ensuring patients have the insights they need to navigate treatment with confidence,' said Vanessa Ghigliotty, Certified Patient Navigator & Chair, Patient Advisory Board, GI Cancers Alliance§. 'For those facing the uncertainty of recurrence, tumor-informed MRD tests like the Oncodetect test can provide clear, timely answers—empowering patients to take an active role in their care and receive the right treatment at the right time for better outcomes.' The Oncodetect test builds on 20 years of genomic testing excellence established by the Oncotype DX Breast Recurrence Score® test. Integrated into a world-class digital experience, supported by the ExactNexus™ technology platform, the Oncodetect test can be ordered with other Exact Sciences tests, including OncoExTra® (comprehensive genomic profiling) and Riskguard® (hereditary cancer testing). With more than 3 million American patients3 eligible for MRD testing, Exact Sciences is well-positioned to shape the future of personalized care. The Oncodetect test is now available. For more information, visit * Circulating tumor DNA † The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test's clinical validation. ‡ Cell-free DNA § Ghigliotty attended the March 2025 Cologuard Classic through a grant from Exact Sciences to the GI Cancers Alliance, which has also received prior funding from the company. References Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology. Santonja et al 2023 EMBO ( Data source on file Internal product profile of the Oncodetect test About the Oncodetect test Developed by Exact Sciences, the Oncodetect test is a tumor-informed molecular residual disease (MRD) test designed to provide a personalized approach to detecting and monitoring residual cancer in patients with solid tumors. By leveraging the company's expertise in whole exome sequencing, the Oncodetect test analyzes circulating tumor DNA (ctDNA) shed into the bloodstream by tumors, offering critical insights into changes in ctDNA levels over time. This quantitative assessment of ctDNA (measured as MTM/mL) helps healthcare providers better understand a patient's MRD status and make informed treatment decisions 4. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook. Oncodetect, Oncotype, Oncotype DX Breast Recurrence Score, and OncoExTra are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences, Cologuard, and Riskguard are trademarks of Exact Sciences Corporation. Oncodetect, Cologuard, Riskguard, and OncoExTra are only available in the United States. Forward-Looking Statement This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding our expectations for the commercialization of the Oncodetect test and the performance of the Oncodetect test in a commercial setting. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
